Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 138

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

From Approvals to Appointments: Who Pays for Psychedelic Therapy, and How?

Ukraine’s Invisible Front: The PTSD Turn in Europe

Weekly Psychedelic Policy Briefing, Nov 13, 2026

Breaking: Helus’ Deuterated Psilocin Hits Primary Endpoint in First Phase 3

Podcast: Compass Files Psilocybin Application with FDA, U.S. Government Taps Mark Cuban to Develop Ibogaine, Psychedelics After the Midterms

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023...

FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR...

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit...

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Psychedelics Weekly – AIMS vs. the DEA: An Update on the...

Establishing the Psychedelic Research Center Consortium​

Key Psychedelic Research Themes in 2022

PT388 – Vital Psychedelic Conversations

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent...

Load more

EDITOR PICKS

From Approvals to Appointments: Who Pays for Psychedelic Therapy, and How?

Ukraine’s Invisible Front: The PTSD Turn in Europe

Weekly Psychedelic Policy Briefing, Nov 13, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©